Biologics and Biosimilars in Psoriasis.

Area of Science:

• Immunodermatology
• Pharmacology
• Biotechnology

Background:

• Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population.
• Research into psoriasis pathogenesis has led to novel therapeutic strategies.
• Biologic agents represent a significant advancement in managing psoriatic disease.

Purpose of the Study:

• To review the current landscape of biologic therapies for psoriasis.
• To discuss the efficacy and safety of various biologic drug classes.
• To highlight the role and considerations of biosimilar drugs in psoriasis treatment.

Main Methods:

• Review of clinical trial data on biologic therapies for psoriasis.
• Analysis of the mechanisms of action for different biologic agents.
• Discussion of biosimilar characteristics and regulatory considerations.

Main Results:

• TNF-α inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and CD-6 inhibitors demonstrate high efficacy in clinical trials.
• These biologic agents generally exhibit favorable safety profiles.
• Biosimilar drugs are structurally similar to reference biologics and require ongoing evaluation.

Conclusions:

• Biologics have transformed psoriasis management, offering effective treatment options.
• Biosimilars present a viable alternative, necessitating long-term efficacy and safety data.
• Continued post-marketing surveillance is essential for understanding the long-term impact of these powerful therapeutic molecules.